Compare MasterCard Inc (MA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Merck & Co., Inc. — how do they compare? MasterCard Inc trades at $587.06 (market cap $503.50B), while Merck & Co., Inc. trades at $145.72 (market cap $351.28B). The key difference: MasterCard Inc is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Merck & Co., Inc. for 98 Days on average.
| MA | MRK | |
|---|---|---|
Market Cap | $503.50B | $351.28B |
Volume | 3,390,859 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $599.86 | $156.43 |
52-Week Low | $471.55 | $82.49 |
Typical Hold Time | 134 Days | 98 Days |
Enterprise Value | $516.53B | $398.04B |
Dividend Yield | 0.61% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $585.52, up 2.71% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $32.79B, net income margin of 46.34%, and impressive ROE of 241.49%. Recent institutional buying activity and positive analyst sentiment (80% buy ratings) support the stock's momentum as it approaches key resistance levels.
Mastercard presents a compelling growth opportunity with expanding digital payment adoption and strong financial performance, though elevated valuation multiples (P/E 31.6, P/S 14.7) and emerging payment technology competition warrant monitoring. The consensus price target of $666.67 suggests 14% upside potential from current levels.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
